Life SciencesLiability
Get a quote

TL;DR

A US policy does not simply stop at the border, but it rarely reaches as far as its summary suggests. Standard general liability wording extends products coverage worldwide for goods made or sold in the United States, then conditions that extension on liability being determined in a suit brought in the US or Canada. The practical translation is worldwide products coverage, adjudicated in North America. Fixing it is a territory decision, not a limits decision, and the two are routinely confused at renewal.

Coverage territory

Does your US policy work outside the United States?

Almost every life sciences company crosses a border before it plans to. A distributor signs in Germany, a platform removes a country restriction from its signup form, a sponsor starts shipping specimens from a trial site abroad, or a CE marking turns into an Authorised Representative agreement with an indemnity in it. None of those feel like insurance decisions at the time.

Each one changes where a claim can be brought, and that is the variable your policy’s coverage territory definition actually turns on. This guide covers the five situations where it matters, what the wording usually says, and what the fix looks like in each case.

The clause everything turns on

“Worldwide” usually carries a proviso.

Widely used US general liability wording defines a coverage territory that includes the United States, its territories and possessions, Puerto Rico, and Canada. It then extends that territory to all other parts of the world for injury or damage arising out of goods or products made or sold within the primary territory.

That extension is real, and it is why a broker can accurately tell a device manufacturer that products coverage is worldwide. The part that gets summarised away is the condition attached to it: that the insured’s responsibility to pay damages is determined in a suit brought within the primary territory, or in a settlement the insurer agrees to.

So a claim from a device sold into Europe may well be covered, provided it is litigated in the United States. A judgment handed down by a court in Munich, Tokyo, or São Paulo is a different question, and it is the one that has to be answered before a distribution agreement is signed rather than after.

Check the same definition on the umbrella and excess layers. A broadened territory on the primary achieves little if the layers above follow narrower wording, and following-form language does not reliably carry a manuscript endorsement upward.

Five situations

Find the one that just happened to you.

Medical device

You signed a distribution agreement outside the US

Does the products policy respond to a claim brought in an EU, UK, or APAC court?

US policy and international sales →

Medical device

You CE marked and appointed an EU Authorised Representative

What does EU MDR actually require on financial coverage, and what does your AR agreement put on you?

EU MDR and products liability territory →

All verticals

You set up a foreign entity, staff, or manufacturing site

Do you need locally admitted policies, and what closes the gap between local terms and your home program?

Controlled master programs and difference in conditions →

Digital health

Your platform opened signup to non-US users

Does the cyber form reach EU and UK users, and are administrative fines insurable there?

Cyber territory for non-US users →

Clinical lab

You began accepting specimens from abroad

Does professional liability territory reach the work, and who insures the foreign collection site?

International specimen processing →

Two terms that collide

The same abbreviations mean different things here.

MDR. Across the rest of this site, MDR means Medical Device Reporting under 21 CFR Part 803, the FDA obligation to report device-associated deaths, serious injuries, and malfunctions. In an international context it means the EU Medical Device Regulation, which governs placing a device on the European market. The two are unrelated, and reading a European contract with the FDA meaning in mind produces expensive confusion.

DIC. In the directors and officers context, Side A difference in conditions is a policy that drops down when a company cannot or will not indemnify its directors. In the international context it means a master layer sitting over locally admitted policies, filling the gap where local terms are narrower or local limits lower. Same three letters, unrelated instruments. Confirm which one is meant before acting on it.

The common error

Raising the limit does not fix the territory.

When an international requirement surfaces, the instinct is to increase the products or cyber limit, because a limit is the number written into the contract and it is the lever everyone knows how to pull.

A higher limit does nothing about a coverage territory that excludes the forum where you were sued. They are independent decisions and they are solved with different instruments: limits with a tower, territory with an endorsement, an international program, or locally admitted paper coordinated by a master policy.

The practical sequence is to establish where a claim can be brought, then fix the wording that governs it, and only then argue about the number.

Frequently asked

Common questions about international coverage and policy territory

Does a US general liability policy cover claims that arise outside the United States?

Partly. Widely used US wording extends products and completed-operations coverage worldwide for goods made or sold within the United States, but conditions that extension on the insured's liability being determined in a suit brought within the United States or Canada, or in a settlement the insurer agrees to. A claim litigated to judgment in a foreign court commonly falls outside that definition. The extension is real; the proviso is what limits it.

What is the difference between a coverage territory problem and a limits problem?

They are independent. A limit is how much the policy pays; a coverage territory determines whether it responds at all in a given forum. Increasing a products or cyber limit does nothing about wording that excludes the jurisdiction where a claim was brought. Territory is fixed with a broadened territory endorsement, an international program, or locally admitted policies coordinated by a master policy, not with a larger tower.

Does EU MDR require a specific amount of insurance?

No. Article 10(16) of Regulation (EU) 2017/745 requires manufacturers to have measures in place to provide sufficient financial coverage for potential liability, proportionate to the risk class, the type of device, and the size of the enterprise. It does not state a limit or prescribe a policy form. Any specific figure being quoted is a market convention or a contractual demand from a distributor or Authorised Representative, and should be verified against the actual agreement.

Why would a life sciences company need locally admitted insurance policies?

A number of countries restrict or prohibit insurance written by carriers not licensed in that country, so cover placed only on US or UK paper can create regulatory and premium tax problems and complicate paying a claim to a locally incorporated entity. Local counterparties, landlords, and public tenders also frequently want evidence of insurance issued in their own market. The usual structure pairs locally admitted policies with a master policy above them providing difference in conditions and difference in limits.

Does a cyber policy cover GDPR fines for a US digital health platform with EU users?

Defense costs usually, fines conditionally. Core cyber insuring agreements are frequently written worldwide, so breach response and liability often reach non-US users. Regulatory defense and penalties is the section that varies: policies typically fund the defense of a proceeding but pay administrative fines only where insurable by law, and the insurability of GDPR fines is determined at member state level and is not uniform. Plan on defense costs being the dependable component.

When does adding foreign users or foreign sales become an insurance event?

At the moment the exposure changes, not at renewal. Opening signup to non-US users, signing a first international distribution agreement, accepting specimens from a foreign collection site, or appointing an EU Authorised Representative each change where a claim can be brought. Most policies impose a duty to report material changes in operations during the policy term, so the practical rule is to treat a change in geography the same way you would treat a new service line.

Primary sources

Two ways to start

Sort out the territory before the contract deadline.

Explore on your own

Reviewing a contract or sizing a first program?

Run your sponsor MSA, GPO supplier agreement, or hospital purchase contract through the free tools. No login, no contact, results in about fifteen minutes. Built for founders and earlier-stage operators who want to understand the requirement first.

Run the MSA DecoderAll free tools →

Talk to a specialist

Scaled operation, a live contract, or a complex program?

Multi-entity structures, high-limit towers, GPO and hospital contract portfolios, transactional and exit diligence. When the program is load-bearing, a specialist reads it clause by clause and rebuilds it to pass. End-of-business-day response.

Request a program reviewHow the review works →

Program review

Send the distribution agreement and the policy. We will tell you whether it reaches.

Request the review

A specialist will reach out by the end of the day.

Programs placed through A-rated specialty markets. Your specialist handles unlimited certificates of insurance, annual coverage reviews, and claims advocacy.